Volitionrx Ltd (VNRX) 5.24 $VNRX VolitionRx to
Post# of 273242
Posted On: 09/19/2016 9:01:42 PM
Volitionrx Ltd (VNRX) 5.24 $VNRX
VolitionRx to Attend Several Conferences in September
PR Newswire - Wed Sep 07, 5:30AM CDT
VolitionRx Limited (NYSE MKT: VNRX), a life sciences company focused on developing diagnostic tests for cancer, today announced that its Chief Executive Officer, Cameron Reynolds, and its Vice President of Investor Relations, Scott Powell, are scheduled to attend and present at several conferences in September.
VNRX: 5.24 (+0.14)
Volition's Nu.Q Triage Colorectal Cancer Screening Test Expected to Reduce Colonoscopy Referral by 25 Percent
PR Newswire - Tue Sep 06, 5:30AM CDT
VolitionRx Limited (NYSE MKT: VNRX), a life sciences company focused on developing diagnostic tests for cancer, today announced that it expects to receive CE Marking on its Nu.Q Triage Colorectal Cancer Screening Test (blood test) in late 2016 and aims to begin marketing the test commencing in early 2017. The test, developed at Volition's laboratories in Belgium in conjunction with Hvidovre Hospital, University of Copenhagen, has demonstrated the potential to reduce colonoscopies by 25% while maintaining almost 97% detection of colorectal cancer. Data supporting the test results will be presented at the forthcoming European Society for Medical Oncology Conference in October 2016. Volition plans initially to focus its launch of the test in the EU member states, which have an aggregate screening age population of approximately 148 million persons.
VNRX: 5.24 (+0.14)
VolitionRx Schedules Product Launch Update Conference Call for Tuesday, September 6, 2016 at 8:30 am ET
PR Newswire - Thu Sep 01, 5:30AM CDT
VolitionRx Limited (NYSE MKT: VNRX), a life sciences company focused on developing diagnostic tests for cancer and other conditions, today announced it will host a conference call on Tuesday, September 6, 2016, at 8:30 a.m. U.S. Eastern Time, to update the market on its commercialization strategy.
VNRX: 5.24 (+0.14)
VolitionRx Announces Second Quarter 2016 Financial Results and Business Update
PR Newswire - Thu Aug 11, 5:30AM CDT
VolitionRx Limited (NYSE MKT: VNRX), a life sciences company focused on developing diagnostic tests for cancer and other conditions, today announced financial results for the second quarter ended June 30, 2016.
VNRX: 5.24 (+0.14)
VolitionRx Schedules Second Quarter 2016 Earnings Conference Call and Business Update for Thursday, August 11, 2016 at 8:30am ET
PR Newswire - Mon Aug 08, 5:30AM CDT
VolitionRx Limited (NYSE MKT: VNRX), a life sciences company focused on developing diagnostic tests for a broad range of cancer types and other conditions, today announced that, in conjunction with the filing of its quarterly report on Form 10-Q for the second quarter ended June 30, 2016, it will host a conference call on Thursday, August 11, 2016, at 8:30 a.m. United States Eastern Time.
VNRX: 5.24 (+0.14)
VolitionRx Engages Edison Advisors as Investor Relations Counsel
PR Newswire - Tue Aug 02, 6:00AM CDT
VolitionRx Limited (NYSE MKT: VNRX), today announced that it has retained Edison Advisors, a global strategic advisory firm, as the Company's investor relations counsel.
VNRX: 5.24 (+0.14)
VolitionRx Appoints Dr. Edward Futcher to Board of Directors
PR Newswire - Fri Jun 24, 6:00AM CDT
VolitionRx Limited (NYSE MKT: VNRX), today announced the appointment of Dr. Edward Futcher to the Company's Board of Directors as a Non-Executive Director, effective June 23, 2016.Dr. Futcher was also appointed to the Company's Audit, Compensation and Nominations and Governance Committees. As a non-executive member of the Company's Board, Dr. Futcher will provide independent expertise and strategic counsel to VolitionRx in connection with the planned commercialization of its NuQ® blood-based diagnostic platform in Europe later this year and the U.S. thereafter.
VNRX: 5.24 (+0.14)
VolitionRx Publishes Study Confirming Stability of Circulating Cell-Free Nucleosomes as Biomarkers for Cancer Diagnostic Blood Tests
PR Newswire - Tue Jun 14, 6:02AM CDT
VolitionRx Limited (NYSE MKT: VNRX), today announced full results from a prospective assessment of pre-analytical variables contributing to the accuracy of its NuQ® blood test that confirm the stability of circulating cell-free nucleosomes (cfnucleosomes) as biomarkers in cancer. The findings were published on 13th June 2016 in the article, "Pre-analytical variables of circulating cell-free nucleosomes containing 5-methylcytosine DNA or histone modification H3K9me3" in the Scandinavian Journal of Clinical and Laboratory Investigation, an international scientific journal focused on clinically-orientated biochemical and physiological research.
VNRX: 5.24 (+0.14)
VolitionRx to Present at Two Upcoming Conferences in June
PR Newswire - Tue May 31, 8:16AM CDT
VolitionRx Limited (NYSE MKT: VNRX) today announced that the Company is scheduled to present at the Marcum MicroCap Conference being held June 1-2 in New York, NY and at the LD Micro Invitational conference, being held June 7-9 in Los Angeles, CA.
VNRX: 5.24 (+0.14)
SeeThruEquity Issues Update Note on VolitionRx (NYSE MKT: VNRX) with a Price Target of $6.70
ACCESSWIRE - Mon May 23, 8:00AM CDT
NEW YORK, NY / ACCESSWIRE / May 23, 2016 / SeeThruEquity, a leading New York City based independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued an update note on VolitionRx Ltd. (NYSE MKT: VNRX).
VNRX: 5.24 (+0.14)
VolitionRx to Present Data Demonstrating Accuracy of NuQ® Blood Test in Detecting Colorectal Cancer at World Endoscopy Organization (WEO) Meeting
PR Newswire - Thu May 19, 6:00AM CDT
VolitionRx Limited (NYSE MKT: VNRX) today announced that its Chief Medical Officer & Head of U.S. Operations, Dr. Jason Terrell, is to present at the World Endoscopy Organization (WEO) Colorectal Cancer Screening Committee Meeting on May 20, 2016, which precedes Digestive Disease Week (DDW), being held May 21-24, 2016 in San Diego, CA. Dr. Terrell will present data from three clinical trials evaluating the Company's NuQ® blood tests for the detection of colorectal cancer and adenomas, or pre-cancerous polyps.
VNRX: 5.24 (+0.14)
VolitionRx Announces First Quarter 2016 Financial Results and Business Update
PR Newswire - Fri May 13, 6:00AM CDT
VolitionRx Limited (NYSE MKT: VNRX), a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, today announced financial results for the first quarter ended March 31, 2016.
VNRX: 5.24 (+0.14)
VolitionRx Initiates Clinical Trial with German Cancer Research Center (DKFZ) to Evaluate NuQ(R) Blood Test for Pancreatic Cancer
PR Newswire - Thu May 12, 6:00AM CDT
VolitionRx Limited (NYSE MKT: VNRX) today announced that it is initiating a study with DKFZ, the German Cancer Research Center, to evaluate VolitionRx's NuQ® blood tests for the detection of pancreatic cancer.
VNRX: 5.24 (+0.14)
VolitionRx Schedules First Quarter 2016 Earnings Conference Call and Business Update for Friday, May 13, 2016 at 8:30am ET
PR Newswire - Mon May 09, 6:00AM CDT
VolitionRx Limited (NYSE MKT: VNRX), a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, today announced that, in conjunction with the filing of its quarterly report on Form 10-Q for the third quarter ended March 31, 2016, it will host a conference call on May 13, 2016, at 8:30 a.m. United States Eastern Time.
VNRX: 5.24 (+0.14)
VolitionRx Announces Study Results Showing NuQ® Blood Test Detects Prostate Cancer Early with Significantly Higher Accuracy than PSA Test
PR Newswire - Wed Apr 20, 8:00AM CDT
VolitionRx Limited (NYSE MKT: VNRX) today announced that a single NuQ® biomarker assay detected 71% of early stage I prostate cancer cases at 93% specificity. This is significantly higher than the most common blood test currently used to detect prostate cancer, the Prostate Specific Antigen (PSA), which is reported to detect 53% of prostate cancers at 73% specificity1. The study was conducted in collaboration with the Surrey Cancer Research Institute at the University of Surrey in the UK. The results are being presented today at the American Association for Cancer Research (AACR) Annual Meeting in New Orleans, LA.
VNRX: 5.24 (+0.14)
VolitionRx Appoints Louise Day as Chief Marketing and Communications Officer
PR Newswire - Thu Apr 14, 6:00AM CDT
VolitionRx Limited (NYSE MKT: VNRX), today announced the appointment of Louise Day as its Chief Marketing and Communications Officer, effective April 11, 2016. Ms. Day will lead VolitionRx communications and develop the Company's branding and global marketing strategy in preparation for the initial market entry of its NuQ® blood-based tests for cancer. The Company expects to commence the European launch of NuQ® in 2016, to be followed by the U.S. and rest of the world.
VNRX: 5.24 (+0.14)
VolitionRx to Present at AACR Annual Meeting and Announce First Results from Prostate Cancer Study
PR Newswire - Fri Apr 08, 6:00AM CDT
VolitionRx Limited (NYSE MKT: VNRX) today announced that first results from a prostate cancer study by the Company will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting, one of the most prestigious meetings on preclinical research in the field of oncology. The meeting is being held April 16-20, 2016 in New Orleans, LA.
VNRX: 5.24 (+0.14)
VolitionRx to Attend Several Conferences in September
PR Newswire - Wed Sep 07, 5:30AM CDT
VolitionRx Limited (NYSE MKT: VNRX), a life sciences company focused on developing diagnostic tests for cancer, today announced that its Chief Executive Officer, Cameron Reynolds, and its Vice President of Investor Relations, Scott Powell, are scheduled to attend and present at several conferences in September.
VNRX: 5.24 (+0.14)
Volition's Nu.Q Triage Colorectal Cancer Screening Test Expected to Reduce Colonoscopy Referral by 25 Percent
PR Newswire - Tue Sep 06, 5:30AM CDT
VolitionRx Limited (NYSE MKT: VNRX), a life sciences company focused on developing diagnostic tests for cancer, today announced that it expects to receive CE Marking on its Nu.Q Triage Colorectal Cancer Screening Test (blood test) in late 2016 and aims to begin marketing the test commencing in early 2017. The test, developed at Volition's laboratories in Belgium in conjunction with Hvidovre Hospital, University of Copenhagen, has demonstrated the potential to reduce colonoscopies by 25% while maintaining almost 97% detection of colorectal cancer. Data supporting the test results will be presented at the forthcoming European Society for Medical Oncology Conference in October 2016. Volition plans initially to focus its launch of the test in the EU member states, which have an aggregate screening age population of approximately 148 million persons.
VNRX: 5.24 (+0.14)
VolitionRx Schedules Product Launch Update Conference Call for Tuesday, September 6, 2016 at 8:30 am ET
PR Newswire - Thu Sep 01, 5:30AM CDT
VolitionRx Limited (NYSE MKT: VNRX), a life sciences company focused on developing diagnostic tests for cancer and other conditions, today announced it will host a conference call on Tuesday, September 6, 2016, at 8:30 a.m. U.S. Eastern Time, to update the market on its commercialization strategy.
VNRX: 5.24 (+0.14)
VolitionRx Announces Second Quarter 2016 Financial Results and Business Update
PR Newswire - Thu Aug 11, 5:30AM CDT
VolitionRx Limited (NYSE MKT: VNRX), a life sciences company focused on developing diagnostic tests for cancer and other conditions, today announced financial results for the second quarter ended June 30, 2016.
VNRX: 5.24 (+0.14)
VolitionRx Schedules Second Quarter 2016 Earnings Conference Call and Business Update for Thursday, August 11, 2016 at 8:30am ET
PR Newswire - Mon Aug 08, 5:30AM CDT
VolitionRx Limited (NYSE MKT: VNRX), a life sciences company focused on developing diagnostic tests for a broad range of cancer types and other conditions, today announced that, in conjunction with the filing of its quarterly report on Form 10-Q for the second quarter ended June 30, 2016, it will host a conference call on Thursday, August 11, 2016, at 8:30 a.m. United States Eastern Time.
VNRX: 5.24 (+0.14)
VolitionRx Engages Edison Advisors as Investor Relations Counsel
PR Newswire - Tue Aug 02, 6:00AM CDT
VolitionRx Limited (NYSE MKT: VNRX), today announced that it has retained Edison Advisors, a global strategic advisory firm, as the Company's investor relations counsel.
VNRX: 5.24 (+0.14)
VolitionRx Appoints Dr. Edward Futcher to Board of Directors
PR Newswire - Fri Jun 24, 6:00AM CDT
VolitionRx Limited (NYSE MKT: VNRX), today announced the appointment of Dr. Edward Futcher to the Company's Board of Directors as a Non-Executive Director, effective June 23, 2016.Dr. Futcher was also appointed to the Company's Audit, Compensation and Nominations and Governance Committees. As a non-executive member of the Company's Board, Dr. Futcher will provide independent expertise and strategic counsel to VolitionRx in connection with the planned commercialization of its NuQ® blood-based diagnostic platform in Europe later this year and the U.S. thereafter.
VNRX: 5.24 (+0.14)
VolitionRx Publishes Study Confirming Stability of Circulating Cell-Free Nucleosomes as Biomarkers for Cancer Diagnostic Blood Tests
PR Newswire - Tue Jun 14, 6:02AM CDT
VolitionRx Limited (NYSE MKT: VNRX), today announced full results from a prospective assessment of pre-analytical variables contributing to the accuracy of its NuQ® blood test that confirm the stability of circulating cell-free nucleosomes (cfnucleosomes) as biomarkers in cancer. The findings were published on 13th June 2016 in the article, "Pre-analytical variables of circulating cell-free nucleosomes containing 5-methylcytosine DNA or histone modification H3K9me3" in the Scandinavian Journal of Clinical and Laboratory Investigation, an international scientific journal focused on clinically-orientated biochemical and physiological research.
VNRX: 5.24 (+0.14)
VolitionRx to Present at Two Upcoming Conferences in June
PR Newswire - Tue May 31, 8:16AM CDT
VolitionRx Limited (NYSE MKT: VNRX) today announced that the Company is scheduled to present at the Marcum MicroCap Conference being held June 1-2 in New York, NY and at the LD Micro Invitational conference, being held June 7-9 in Los Angeles, CA.
VNRX: 5.24 (+0.14)
SeeThruEquity Issues Update Note on VolitionRx (NYSE MKT: VNRX) with a Price Target of $6.70
ACCESSWIRE - Mon May 23, 8:00AM CDT
NEW YORK, NY / ACCESSWIRE / May 23, 2016 / SeeThruEquity, a leading New York City based independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued an update note on VolitionRx Ltd. (NYSE MKT: VNRX).
VNRX: 5.24 (+0.14)
VolitionRx to Present Data Demonstrating Accuracy of NuQ® Blood Test in Detecting Colorectal Cancer at World Endoscopy Organization (WEO) Meeting
PR Newswire - Thu May 19, 6:00AM CDT
VolitionRx Limited (NYSE MKT: VNRX) today announced that its Chief Medical Officer & Head of U.S. Operations, Dr. Jason Terrell, is to present at the World Endoscopy Organization (WEO) Colorectal Cancer Screening Committee Meeting on May 20, 2016, which precedes Digestive Disease Week (DDW), being held May 21-24, 2016 in San Diego, CA. Dr. Terrell will present data from three clinical trials evaluating the Company's NuQ® blood tests for the detection of colorectal cancer and adenomas, or pre-cancerous polyps.
VNRX: 5.24 (+0.14)
VolitionRx Announces First Quarter 2016 Financial Results and Business Update
PR Newswire - Fri May 13, 6:00AM CDT
VolitionRx Limited (NYSE MKT: VNRX), a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, today announced financial results for the first quarter ended March 31, 2016.
VNRX: 5.24 (+0.14)
VolitionRx Initiates Clinical Trial with German Cancer Research Center (DKFZ) to Evaluate NuQ(R) Blood Test for Pancreatic Cancer
PR Newswire - Thu May 12, 6:00AM CDT
VolitionRx Limited (NYSE MKT: VNRX) today announced that it is initiating a study with DKFZ, the German Cancer Research Center, to evaluate VolitionRx's NuQ® blood tests for the detection of pancreatic cancer.
VNRX: 5.24 (+0.14)
VolitionRx Schedules First Quarter 2016 Earnings Conference Call and Business Update for Friday, May 13, 2016 at 8:30am ET
PR Newswire - Mon May 09, 6:00AM CDT
VolitionRx Limited (NYSE MKT: VNRX), a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, today announced that, in conjunction with the filing of its quarterly report on Form 10-Q for the third quarter ended March 31, 2016, it will host a conference call on May 13, 2016, at 8:30 a.m. United States Eastern Time.
VNRX: 5.24 (+0.14)
VolitionRx Announces Study Results Showing NuQ® Blood Test Detects Prostate Cancer Early with Significantly Higher Accuracy than PSA Test
PR Newswire - Wed Apr 20, 8:00AM CDT
VolitionRx Limited (NYSE MKT: VNRX) today announced that a single NuQ® biomarker assay detected 71% of early stage I prostate cancer cases at 93% specificity. This is significantly higher than the most common blood test currently used to detect prostate cancer, the Prostate Specific Antigen (PSA), which is reported to detect 53% of prostate cancers at 73% specificity1. The study was conducted in collaboration with the Surrey Cancer Research Institute at the University of Surrey in the UK. The results are being presented today at the American Association for Cancer Research (AACR) Annual Meeting in New Orleans, LA.
VNRX: 5.24 (+0.14)
VolitionRx Appoints Louise Day as Chief Marketing and Communications Officer
PR Newswire - Thu Apr 14, 6:00AM CDT
VolitionRx Limited (NYSE MKT: VNRX), today announced the appointment of Louise Day as its Chief Marketing and Communications Officer, effective April 11, 2016. Ms. Day will lead VolitionRx communications and develop the Company's branding and global marketing strategy in preparation for the initial market entry of its NuQ® blood-based tests for cancer. The Company expects to commence the European launch of NuQ® in 2016, to be followed by the U.S. and rest of the world.
VNRX: 5.24 (+0.14)
VolitionRx to Present at AACR Annual Meeting and Announce First Results from Prostate Cancer Study
PR Newswire - Fri Apr 08, 6:00AM CDT
VolitionRx Limited (NYSE MKT: VNRX) today announced that first results from a prostate cancer study by the Company will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting, one of the most prestigious meetings on preclinical research in the field of oncology. The meeting is being held April 16-20, 2016 in New Orleans, LA.
VNRX: 5.24 (+0.14)
(0)
(0)Scroll down for more posts ▼